Clinical trials

AUTO 1 SL1 - Obecabtagene

• IMP: Obecabtagene Autoleucel
• Obe-cel in severe, refractory SLE - Health Research Authority (opens in a new tab)

ObiVas

• IMP: Obinutuzumab and rituximab
• ISRCTN – ISRCTN13069630: Obinutuzumab compared with rituximab for treating ANCA-associated vasculitis (opens in a new tab)

Alentis

• IMP: ALE.F02
• Study Details | NCT06047171 | Rescue of Nephrons With ALE.F02 (RENAL-F02) | ClinicalTrials.gov (opens in a new tab)

Novartis CLNP023R12201 Iptacopan

• IMP: iptacopan
• Study Details | NCT06388941 | Iptacopan in Patients With ANCA Associated Vasculitis | ClinicalTrials.gov (opens in a new tab)

Good Ides 2

• IMP: imlifidase
• Study Details | NCT05679401 | A Study With Imlifidase in Anti-GBM Disease | ClinicalTrials.gov

NS229

• IMP: NS229
• Trial of efficacy and safety of NS-229 versus placebo in patients with Eosinophilic Granulomatosis – Health Research Authority

MANDARA

• IMP: Benralizumab compared to Mepolizumab
• A study of benralizumab in EGPA (also known as Churg-Strauss Syndrome) – Health Research Authority

RACEMATE

• IMP: Tezepelumab
• RACEMATE – Health Research Authority

REGENCY

• IMP: Obinutuzumab
• CA41705 – The efficacy and safety of obinutuzumab in patients with lupus nephritis – Health Research Authority

Novartis CLNP023K12201 Lupus

• IMP: LNP023
• LNP023K12201 – Health Research Authority

Amgen 2024003

• IMP: Inebilizumab and Blinatumomab
• Study Details | NCT06570798 | A Phase 2a Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases | ClinicalTrials.gov

ALLEGORY (Gazyva in Extrarenal Lupus)

• IMP: Obinutuzumab
• Study Details | NCT04963296 | A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus | ClinicalTrials.gov

Iptacopan

IMP: Iptacopan

IM026-024 Lupus (BMS)

• IMP: Afimetoran
• IM026-024: Phase 2, BMS-986256 Compared with Placebo in Participants with Active SLE – Health Research Authority

Lavender – AZ_275711 Skin Lupus

• IMP: Anifrolumab

AUTO 1 SL1 – Obecabtagene

• IMP: Obecabtagene autoleucel
• Obe-cel in severe, refractory SLE – Health Research Authority

Novartis CYTB23I12201

• IMP: Rapcabtagene autoleucel

DUPLEX 021FSG16010

IMP: Sparsentan (dual endothelin receptor and angiotensin receptor blocker)
021FSG16010 – DUPLEX, Patients with FSGS – Health Research Authority

TURING

IMP: Rituximab
TURING – Health Research Authority

PROTECT IgA 021IGAN17001

IMP: Sparsentan
PROTECT 021IGAN17001 – Health Research Authority

Vera VT

IMP: Atacicept
Study Details | NCT07020923 | Monthly Dosing of Atacicept in IgAN | ClinicalTrials.gov

SPARTAN

IMP: Sparsentan

SPARTAN v1.0 – Health Research Authority

Novartis CLNP023A2002B Rollover Study

IMP: iptacopan

Study Details | NCT04557462 | A Rollover Extension Program to Evaluate the Long-term Safety and Tolerability of Iptacopan/LNP023 in Participants With Primary IgA Nephropathy | ClinicalTrials.gov

ORIGIN 3 (Vera)

IMP: Atacicept

ORIGIN 3 – Health Research Authority

ALXN1210-IgAN-320 (I CAN)

IMP: Ravulizumab

ALXN1210-IgAN-302 – I CAN: Phase 3 Study of Ravulizumab in Adults with IgA Nephropathy – Health Research Authority

Origin Extend (Vera) VT-001-0051

IMP: Atacicept

Study Details | NCT06674577 | A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept | ClinicalTrials.gov

Rainier AIS-D08/479

IMP: Povetacicept

RAINIER – Health Research Authority